Escolar Documentos
Profissional Documentos
Cultura Documentos
InsulinPharmacology,TypesofRegimens,andAdjustmentsEndotextNCBIBookshelf
NCBIBookshelf.AserviceoftheNationalLibraryofMedicine,NationalInstitutesofHealth.
DeGrootLJ,BeckPeccozP,ChrousosG,etal.,editors.Endotext[Internet].SouthDartmouth(MA):MDText.com,Inc.2000.
InsulinPharmacology,TypesofRegimens,andAdjustments
LisaKroon,PharmD,CDE
ProfessorandExecutiveViceChair,DepartmentofClinicalPharmacy,SchoolofPharmacy,UniversityofCaliforniaSanFrancisco,SanFrancisco,CA
kroonl@pharmacy.ucsf.edu
IraD.Goldfine,M.D.
ProfessorofMedicine,DepartmentofMedicine,DiabetesandEndocrineResearch,UniversityofCaliforniaSanFrancisco/Mt.ZionMedicalCenter,San
Francisco,CA
ira.goldfine@ucsf.edu
SinanTanyolac,M.D.
VisitingScientist,DepartmentofMedicine,UniversityofCaliforniaSanFrancisco,SanFrancisco,CA
stanyolac@gmail.com
LastUpdate:October1,2010.
INTRODUCTION
Withtheintroductionofseveralnewinsulinssince1996,insulintherapyoptionsfortype1andtype2diabeticshave
expanded.Insulintherapiesarenowabletomorecloselymimicphysiologicinsulinsecretionandthusachievebetter
glycemiccontrolinpatientswithdiabetes.Thischapterreviewsthepharmacologyofinsulins(usingacomparative
approach),typesofinsulinregimensandtherapeuticadjustmentofthem,andprovidesanoverviewofinsulinpump
therapy.
PHARMACOLOGY
In1922,Canadianresearcherswerethefirsttodemonstrateaphysiologicresponsetoinjectedanimalinsulininapatient
withtype1diabetes.In1955,insulinwasthefirstproteintobefullysequenced.Theinsulinmoleculeconsistsof51
aminoacidsarrangedintwochains,anAchain(21aminoacids)andBchain(30aminoacids)thatarelinkedbytwo
disulfidebonds[1] (Figure1).ProinsulinistheinsulinprecursorthatistransportedtotheGolgiapparatusofthebeta
cellwhereitisprocessedandpackagedintogranules.Proinsulin,asinglechain86aminoacidpeptide,iscleavedinto
insulinandCpeptide(aconnectingpeptide)botharesecretedinequimolarportionsfromthebetacelluponstimulation
fromglucoseandotherinsulinsecretagogues.WhileCpeptidehasnoknownphysiologicfunction,itcanbemeasured
andifpresent,indicatesapersonhasfunctioningbetacells.
Figure1
InsulinStructure
Insulinexertsitseffectonglucosemetabolismbybindingtoinsulinreceptorsthroughoutthebody.Uponbinding,
insulinpromotesthecellularuptakeofglucoseintofatandskeletalmuscleandinhibitshepaticglucoseoutput,thus
loweringthebloodglucose.(seeInsulinsignalingandaction:glucose,lipids,protein)
Commerciallyavailableinsulinsareusedforallpatientswithtype1diabetesinwhominsulinisrequiredforsurvival,
andforpatientswithtype2diabeteswhendiet/exercise,oralagentsandotherinjectablehypoglycemicagents(i.e.,
incretinemimeticagents/GLP1analogs)nolongerprovideadequateglucosecontrol.
SourcesofInsulin
WiththeavailabilityofhumaninsulinbyrecombinantDNAtechnologyinthe1980s,useofanimalinsulindeclined
http://www.ncbi.nlm.nih.gov/books/NBK278938/?report=printable
1/24
25/06/2015
InsulinPharmacology,TypesofRegimens,andAdjustmentsEndotextNCBIBookshelf
dramatically.Beefinsulin,beefporkandporkinsulinarenolongercommerciallyavailable.TheFDAmayallowfor
personalimportationofbeefinsulinfromaforeigncountryifapatientcannotbetreatedwithhumaninsulin[2] .Beef
insulindiffersfromhumaninsulinby3aminoacidsandporkinsulindiffersbyoneaminoacid[3] .
Currently,intheUSA,mostinsulinsusedareeitherhumaninsulinand/oranalogsofhumaninsulin.Therecombinant
DNAtechniqueforhumaninsulininvolvesinsertionofthehumanproinsulingeneintoeitherSaccharomycescerevisiae
(bakersyeast)oranonpathogeniclaboratorystrainofEscherichiacoli(Ecoli)whichserveastheproduction
organism.Humaninsulinisthenisolatedandpurified[4] [5] [6] [7] [8] [9] [10] [11] .
InsulinAnalogs
RecombinantDNAtechnologyhasallowedforthedevelopmentandproductionofanalogstohumaninsulin.With
analogs,theinsulinmoleculestructureismodifiedslightlytoalterthepharmacokineticspropertiesoftheinsulin,
primarilyaffectingtheabsorptionofthedrugfromthesubcutaneoustissue.TheB26B30regionoftheinsulinmolecule
isnotcriticalforinsulinreceptorrecognitionanditisinthisregionthataminoacidsaregenerallysubstituted[12] .
Thus,theinsulinanalogsarestillrecognizedbyandbindtotheinsulinreceptor.Thestructuresofthreeinsulinanalogs
areshowninFigure2(insulinaspart,lisproandglulisine)andFigure3(insulinglargineanddetemir).
Figure2
InsulinAspart,GlulisineandLisproStructures
http://www.ncbi.nlm.nih.gov/books/NBK278938/?report=printable
2/24
25/06/2015
Figure3
InsulinPharmacology,TypesofRegimens,andAdjustmentsEndotextNCBIBookshelf
InsulinGlargineandDetemirStructures
Becauseinsulinanalogsaremodifiedhumaninsulin,thesafetyandefficacyprofilesoftheseinsulinshavebeen
comparedtohumaninsulin[13] .InsulinandIGF1receptorbindingaffinities(IGFinsulinlikegrowthfactor),
metabolicandmitogenicpotenciesofinsulinlispro,insulinaspart,insulinglargineandinsulindetemirrelativetohuman
insulinhasbeenassessed.Insulinlisproandaspartaresimilartohumaninsulinonalloftheaboveparameters,except
insulinlisprowasfoundtobe1.5foldmorepotentinbindingtotheIGF1receptorcomparedtohumaninsulin.Insulin
glarginewasfoundtohavea6to8foldincreaseinmitogenicpotencyandIGF1receptoraffinitycomparedtohuman
insulin.Insulindetemirwasfoundtotobemorethan5foldlesspotentthanhumaninsulininbiningtoIGF1.Whilethe
clinicalsignificanceofthesedifferencesisnotknown,theylikelydonotrepresentanysignificantconcern[14] .
Immunogenicity
Becauseporkandbeefinsulindifferfromhumaninsulinby1and3aminoacidsrespectively,theyaremore
immunogenicthanexogenoushumaninsulin.Olderformulationsofinsulinwerelesspure,containingisletcellpeptides,
proinsulin,Cpeptide,pancreaticpolypeptides,glucagons,andsomastostatin,whichcontributedtoimmunogenicityof
insulin[15] .Componentsofinsulinpreparations(e.g.,zinc,protamine)andsubcutaneousinsulinaggregatesarealso
thoughttocontributetoantibodyformation[16] .Commerciallyavailablehumaninsulinsarenowvirtuallyfreeof
contaminantsandcontain<1ppmofproinsulin(alsoreferredtoaspurified)[17] .Insulinsideeffectssuchas
localorsystemichypersensitivity,lipodystrophy,andantibodyproductioncausinginsulinresistance,arenowrarely
seenwithexogenoushumaninsulin[18] .Becauseoftheavailabilityofhumaninsulinandtheincreasedpotentialfor
animalsourceinsulintobeimmunogenic,animalsourceinsulinsarenowrarelyusedandpeoplewithdiabetesshouldbe
initiatedonhumaninsulin.
Therarehypersensitivityresponsestoinsulincanbeimmediatetype,localorsystemicIgEmediatedreactions[19] .
http://www.ncbi.nlm.nih.gov/books/NBK278938/?report=printable
3/24
25/06/2015
InsulinPharmacology,TypesofRegimens,andAdjustmentsEndotextNCBIBookshelf
Patientswhoexperienceatrueallergicreactiontoinsulinoftenhavereceivedinsulininthepast,andexperiencethe
allergicreactionafterinsulinisrestarted.Anotherallergicreactionseenwithanimalinsulinswasadelayedlocalreaction
thatwasIgGmediated[20] .InsulintherapycanalsoresultintheproductionofinsulinantibodiesoftheIgGclass,
whichneutralizeinsulin.AnimmunologicalinsulinresistancecanoccurinpatientswithveryhightitersofIgG
antibodies.
Lipodystrophyseenwithinsulinreferstotwoconditions:lipoatrophyandlipohypertrophy.Lipoatrophyisanimmune
mediatedconditioninwhichthereislossoffatattheinsulininjectionsites[21] .Lipoatrophyoccursmuchless
frequentlywithpurifiedhumaninsulins.Treatmentforpatientswhowereonananimalinsulinwasinjectionwithhuman
insulinattheatrophiedsite.Lipohypertrophyisanonimmunologicalsideeffectofinsulinresultingfromrepeated
administrationofinsulinatthesameinjectionsite.
Concentration
IntheUnitedStates,allinsulinsareavailableintheconcentrationof100units/ml(denotedasU100).Insulinsyringes
aredesignedtoaccommodatethisconcentrationofinsulin.Regularhumaninsulin(HumulinR,Lilly)isavailableina
moreconcentratedinsulin,U500(500units/ml),howeverthispreparationisusedprimarilyinaspecializedinstitutional
settingorforrarecasesofextremeinsulinresistance,whereverylargedosesofinsulin(generally>200unitsperday)
arerequired.SpecificsyringesforU500insulinarenotavailableandextremecautionmustbetakenaseachmarked
unitonaU100syringewillactuallydeliver5unitsofinsulin.
OutsidetheUnitedStates,alessconcentratedinsulinpreparation,U40,(40units/ml)isstillavailableandsometimes
used.SpecificU40syringesareusedwiththisinsulin.Itisimportantthatpatientstravelingfromonecountrytothe
next,beawareoftheconcentrationofinsulintheyuse,andthattheappropriatesyringeisused.
PhysicalandChemicalProperties
Regularhumaninsuliniscrystallinezincinsulindissolvedinaclearsolution.Itmaybeadministeredbyanyparenteral
route:subcutaneous,intramuscular,orintravenous.Insulinaspart,glulisineandlisproarealsosolublecrystallinezinc
insulin,butareintendedforsubcutaneous(subQ)injection.NPH,orneutralprotamineHagedorn,isasuspensionof
regularinsulincomplexedwithprotaminethatdelaysitsabsorption.Insulinsuspensionsshouldnotbeadministered
intravenously.Allinsulins,exceptinsulinglargine,areformulatedtoaneutralpH.
LongactingInsulinglargineisasoluble,clearinsulin,andhasapHof4.0.ItsacidicpHiscriticalforitssubQ
absorptioncharacteristicsandwillbediscussedfurtherunderpharmacokinetics.Insulinglargineshouldnotbemixed
withotherinsulins,andshouldonlybeadministeredsubcutaneously[22] .
InsulindetemirisalongactinginsulinanalogthathasafattyacidcoupledtoitsothatitbindstoalbumininthesubQ
tissueresultingindelayedabsorption,proloningitsdurationofaction.Likeinsulinglargine,insulindetemirshouldnot
bemixedwithotherinsulins,andshouldbeinjectedsubcutaneously.
Pharmacokinetics
Absorption
InsulinadministeredviaSCinjectionisabsorbeddirectlyintothebloodstream,withthelymphaticsystemplayinga
minorroleintransport[23] .TheabsorptionofhumaninsulinaftersubQabsorptionistheratelimitingstepofinsulin
activity.ThisabsorptionisinconsistentwiththecoefficientsofvariationofT50%(timefor50%oftheinsulindosetobe
absorbed)varying~25%withinanindividualandupto50%betweenpatients[24] [25] .Mostofthisvariabilityof
insulinabsorptioniscorrelatedtobloodflowdifferencesatthevarioussitesofinjection(abdomen,deltoid,gluteus,and
thigh)[26] .Forregularinsulin,theimpactofthisisa~2timesfasterrateofabsorptionfromtheabdomenthanother
subcutaneoussites[27] .Theclinicalsignificanceofthisisthatpatientsshouldavoidrandomuseofdifferentbody
http://www.ncbi.nlm.nih.gov/books/NBK278938/?report=printable
4/24
25/06/2015
InsulinPharmacology,TypesofRegimens,andAdjustmentsEndotextNCBIBookshelf
regionsfortheirinjections.Forexample,ifapatientpreferstousetheirthighforanoontimeinjection,thissiteshouldbe
usedconsistentlyforthisinjection.Forsimplicity,however,theabdomenisoftenrecommendedasthepreferredsiteof
injectionbecauseitistheleastsusceptibletofactorsaffectinginsulinabsorption(seeTable1).Insulinaspart,glulisine
andlisproappeartohavelessdaytodayvariationinabsorptionratesandalsolessabsorptionvariationfromthe
differentbodyregions[28] [29] [30] [31] .Insulinglarginespharmacokineticprofileissimilarafterabdominal,
deltoidorthighSCadministration[32] .
AgeneralprincipleforfactorsthatcanalterinsulinabsorptionisthatwhenlocalbloodflowinthesubQtissueis
changed,theabsorptionrateofinsulinwillalsobeaffected.AfactorthatincreasessubQbloodflowwillincreasethe
absorptionrateandviceversa.SeeTable1forfactorsthataffectinsulinabsorption.
Table1
FactorsAffectingInsulinAbsorption([33][34][35])
Factor
Comment
Exerciseofinjectedarea
Strenuousexerciseofalimbwithin1hourofinjection.Clinicallysignificantforregular
humaninsulin.
Localmassage
WhileitisOKtopressontheinjectionsitetopreventseepage,thesiteshouldnotbe
rubbedvigorouslyormassaged.
Temperature
Heatcan
increaseabsorptionrate.Avoidthesauna,shower,hotbathsoonafterinjection.
Coldhastheoppositeeffect.
Siteofinjection
Insulinisabsorbedfasterfromtheabdomen.Lessclinicallyrelevantwithrapidacting
insulins,insulinglargineandinsulindetemir.
Lipohypertrophy
Injectionintohypertrophiedareasdelaysinsulinabsorption.
Jetinjectors
Increase
absorptionrate.
Insulinmixtures
Absorptionratesareunpredictablewhensuspensioninsulinsarenotmixedadequately(i.e.,
theyneedtoberesuspended).
Insulindose
Largerdoseshavedelayinactionand
increasedduration.
Physicalstatus(solublevs. Suspensioninsulinsmustbesufficientlyresuspendedpriortoinjectiontoreducevariability.
suspension)
Distribution
CirculatinginsulinisdistributedinequilibriumbetweenfreeinsulinandinsulinboundtoIgGantibodies[36] .The
presenceofinsulinantibodiescandelaytheonsetofinsulinactivity,reducethepeakconcentrationoffreeinsulin,and
prolongthebiologichalflifeofinsulin[37] .
Elimination
Thekidneysandliveraccountforthemajorityofinsulindegradation.Normally,theliverdegrades~60%ofinsulin
releasedbythepancreas(insulindeliveredthroughportalveinbloodflow)andthekidneys~3545%[38] .When
insulinisinjectedexogenously,thedegradationprofileisalteredsinceinsulinisnolongerdelivereddirectlytotheportal
vein.ThekidneyhasagreaterroleininsulindegradationwithsubQinsulin(~60%),withtheliverdegrading~3040%[
39] .
Becausethekidneysareinvolvedinthedegradationofinsulin,renaldysfunctionwillreducetheclearanceofinsulinand
prolongitseffect.Thisdecreasedclearanceisseenwithbothendogenousinsulinproduction(eithernormalproduction
orthatstimulatedbyoralagents)andexogenousinsulinadministration.Renalfunctiongenerallyneedstobegreatly
diminishedbeforethisbecomesclinicallysignificant[40] .
http://www.ncbi.nlm.nih.gov/books/NBK278938/?report=printable
5/24
25/06/2015
InsulinPharmacology,TypesofRegimens,andAdjustmentsEndotextNCBIBookshelf
Pharmacodynamics
Theonset,peak,anddurationofeffectarethemostclinicallysignificantdifferencesamongtheinsulins.Insulin
pharmacodynamicsreferstothemetaboliceffectofinsulin.Commerciallyavailableinsulinscanbecategorizedasrapid
acting,shortacting,intermediateacting,andlongacting.ThecurrentinsulinsavailableintheUnitedStatesarelistedin
Table2.Insulinpharmacodynamics(i.e.,onset,peakandduration)ofthevariousinsulins)areshowninTable3.Itis
importanttonotethatrangesarelistedfortheonset,peakandduration,accountingforintra/interpatientvariability.
Eachpatientwillhaveanindividualpatternofresponse.Byhavingthepatientselfmonitortheirbloodglucose
frequently,thepatientspecifictimeactionprofileofthespecificinsulincanbebetterappreciated.Figures4a4c[41] [
42] [43] [44]
graphicallyshowthetimeactivityprofilesforthevariousinsulins.
Table2I
nsulinsCommerciallyAvailableintheUS
Category/Nameof
Insulin
Source
BrandName(manufacturer)
Preparation(s)
RapidActing
InsulinLispro
InsulinAspart
InsulinGlulisine
Recombinant
DNARecombinant
DNA
RecombinantDNA
Humalog(Lilly)Novolog(Novo vial,cartridge,disposablepenvial,
Nordisk)
cartridge,disposablepen
Apidra(sanofiaventis)
vial,disposablepen
ShortActing
Regular
Human
RecombinantDNA
HumulinR(Lilly)NovolinR
(NovoNordisk)
vialvial
IntermediateActing RecombinantDNA
NPH
Human
HumulinN(Lilly)NovolinN
(NovoNordisk)
vial,disposablepenvial
LongActing
InsulinDetemir
InsulinGlargine
Recombinant
DNARecombinant
DNA
Levemir(NovoNordisk
)Lantus(sanofiaventis)
vial,disposablepenvial,cartridge,
disposablepen
InsulinMixtures
NPH/Regular
(70%/30%)
Human
Lispro
Protamine/Lispro
(50%/50%)
Lispro
Protamine/Lispro
(75%/25%)
Aspart
Protamine/Aspart
(70%/30%)
Recombinant
DNARecombinant
DNA
RecombinantDNA
RecombinantDNA
Humulin70/30(Lilly)Novolin
70/30(NovoNordisk)
HumalogMix50/50(Lilly)
HumalogMix75/25(Lilly)
NovologMix70/30(Novo
Nordisk
vial,disposablepenvial
vial,disposablepen
vial,disposablepen
vial,disposablepen
Note:Allinsulinanalogsareavailablebyprescriptiononly.OnAugust17,2009,NovoNordiskannouncedthe
NovolinInnoletR,N,and70/30devicesandtheNovolinR,Nand70/30PenFillcartridgeswouldnolongerbe
availableafterDecember31,2009.
Table3I
nsulinPharmacodynamics([45][46][47][48][49][50][51][52][53][54][55][56][57])
http://www.ncbi.nlm.nih.gov/books/NBK278938/?report=printable
6/24
25/06/2015
InsulinPharmacology,TypesofRegimens,andAdjustmentsEndotextNCBIBookshelf
Insulin
Onset(hr)
Peak(hr)
Duration(hr) Appearance
InsulinLispro
within15min 1
35
Clear
InsulinAspart
within15min 13
35
Clear
InsulinGlulisine .25.5
.51
Clear
Regular
24
58
Clear
NPH
12
410
14+
Cloudy
InsulinDetemir
34
68(thoughrelativelyflat) upto2024
Clear
InsulinGlargine
1.5
flat
24
Clear
LisproMix50/50 .25.5
.53
1424
Cloudy
LisproMix75/25 .255
.52.5
1424
Cloudy
AspartMix70/30 .1.2
14
1824
Cloudy
Note:Patientspecificonset,peak,durationmayvaryfromtimeslistedintable,
Peakanddurationareoftenverydosedependentwithshorterdurationofactionswith
smallerdosesandviceversa.
Figure4a
PharmacodynamicProfilesofaRapidInsulinAnalog(insulinlispro)andRegularInsulin.
http://www.ncbi.nlm.nih.gov/books/NBK278938/?report=printable
7/24
25/06/2015
Figure4b
InsulinPharmacology,TypesofRegimens,andAdjustmentsEndotextNCBIBookshelf
PharmacodynamicProfilesofLongActingandIntermediateActing
BasalInsulins.
http://www.ncbi.nlm.nih.gov/books/NBK278938/?report=printable
8/24
25/06/2015
Figure4c
InsulinPharmacology,TypesofRegimens,andAdjustmentsEndotextNCBIBookshelf
PharmacodynamicProfile:LisproNPLinComparisonwithNPH
DoseDependentEffect
ThepharmacodynamicsofregularandNPHareparticularlyaffectedbythesizeofthedose[58] .Largerdosescan
causeadelayinthepeakandincreasethedurationofaction.Forexample,injecting4unitsofNPHwillhavea
significantlydifferenttimeactionprofilecomparedto30unitsofNPH.
RapidActingInsulins
InsulinLispro(Humalog)
Insulinlispro[Lys(B28),Pro(B29)]isaninsulinanalogthatwasapprovedin1996(Humalog).TheB28(proline),B29
(lysine)aminoacidsequenceoftheinsulinmoleculeisreversedtobelysineprolineresultinginarapidabsorption,
within15minutes.Becauseitisabsorbedmorerapidly,itsonsetandpeakaresooner(anddurationshorter)comparedto
regularinsulin.Insulinlisproisalsoapprovedforinjectionimmediatelyafterameal.Becauseinsulinlisprocanbe
injectedjustbefore(orafter)themealversuswaiting30minuteswithregularinsulin,patientsmayfinditprovidesthem
withmoreflexibilityandconveniencefortheirmealtimeinsulininjection.Insulinlisprocanbemoreeffectivein
loweringpostprandialbloodglucoselevelsandhasareducedriskofhypoglycemiacomparedtoregularinsulin[59] [
60] [61]
.Thereasoninsulinlisproisassociatedwithlesshypoglycemiaisduetobettermatchingofinsulineffectand
foodabsorption[62] .Insulinlisprohasbeenstudiedforuseininsulinpumpsand,FDAapprovedforthisindicationin
2004.[63] [64] [65] .Intherarecaseofseverehumaninsulinallergy,insulinlisprohasbeenshowntobeless
immunogenic[66] .
InsulinAspart(Novolog)
http://www.ncbi.nlm.nih.gov/books/NBK278938/?report=printable
9/24
25/06/2015
InsulinPharmacology,TypesofRegimens,andAdjustmentsEndotextNCBIBookshelf
InsulinaspartisahumaninsulinanalogapprovedJune7,2000(Novolog).TheB28aminoacidprolineissubstituted
withasparticacidresultinginarapidonsetofactivity.Insulinaspartshouldbeinjected510minutesbeforethemeal.
Advantageslistedaboveforinsulinlisproarethesameforinsulinaspart[67] .TheinsulinaspartisFDAapprovedfor
useininsulinpumps[68] [69] .
Whileonamolarbasisinsulinaspartandlisprohaveidenticalinvivopotencycomparedtoregularhumaninsulin,
higherpeakconcentrationsareachievedwiththerapidactinginsulins[70] .Thus,whilea1:1conversionisoftenused
fortheinitialswitchfromregularinsulintoinsulinaspart,glulisineorlispro,overtime,apatientsrapidacting
insulindosemayneedtobeadjusted,oftenreduced.Thisdosingchangeisalsoduetothebettermatchingofthepeakof
theinsulinwiththemeal,thusachievingbetterpostprandialcontrol.
InsulinGlulisine(Apidra)
Insulinglulisineisarapidactinginsulinanaloguethatdiffersfromhumaninsulininthattheaminoacidasparagineat
positionB3isreplacedbylysineandthelysineinpositionB29isreplacedbyglutamicacid.Chemically,itis3Blysine
29Bglutamicacidhumaninsulin.Wheninjectedsubcutaneously,itsonsetofactionismorerapidandachieveshigher
concentrationscomparedtohumaninsulinonaunitperunitbasis.Whenusedasamealtimeinsulin,thedoseshouldbe
givenwithin15minutesbeforeamealorwithin20minutesafterstartingameal.Insulinglulisinealsoisbeingusedin
insulinpumps[71] .InsulinglulisinehasbeenavailableinUSAsince2007andFDAapprovedin2004.
ShortActingInsulin(Regular)
Regularinsulinhasanonsetofactionof3060minutes.Itshouldbeinjectedapproximately30minutesbeforethemeal.
Adherencetothisschedulecanbeinconvenientanddifficultforsomepatients.
IntermediateActingInsulins(NPH)
NPH,whichstandsforNeutralProtamineHagedorn,wascreatedin1936byHansChristianHagedornandB.Norman
Jensen.Thesescientistsdiscoveredthattheeffectsofsubcutaneouslyinjectedinsulincouldbeprolongedbytheaddition
ofprotamine,aproteinthattheyobtainedfromthe"milt"orsemenofrivertrout.NPHinsuliniscategorizedasan
intermediateactinginsulin,whoseonsetofactionisapproximately2hours,peakeffectat614hours,anddurationof
actionupto24hours(dependingonthesizeofthedose).Intermediateactinginsulinscanserveabasalinsulinand/or
prandialinsulindependingontimeofadministration.NPHinsulinisavailableinvariouscombinationswitheither
regularinsulinorshortactinginsulins(Table2).
LongActingInsulins
Longactinginsulinsservetoprovideabasal(orbaseline)levelofinsulin.
InsulinGlargine(Lantus)
Insulinglargine(21AGly30BaLArg30BbLArghumaninsulin)isaninsulinanalogapprovedApril20,2000
(Lantus).Itconsistsoftwomodificationstohumaninsulin.TwoargininesareaddedtotheCterminusoftheBchain
shiftingtheisoelectricpointoftheinsulinfromapHor5.4to6.7[72] .Thischangemakestheinsulinmoresolubleat
anacidicpHandinsulinglargineisformulatedatapHof4.0[73] .ThesecondmodificationisattheA21position,
whereasparagineisreplacedbyglycine.Thissubstitutionpreventsdeamidationanddimerisationthatwouldoccurwith
acidsensitiveasparagine.Wheninsulinglargineisinjectedintosubcutaneoustissue,whichisatphysiologicpH,the
acidicsolutionisneutralized.Microprecipitatesofinsulinglargineareformed,fromwhichsmallamountsofinsulinare
releasedthroughouta24hourperiod,resultinginalowlevelofinsulinthroughouttheday[74] .Thebiologicalactivity
ofinsulinglargineisduetoitsabsorptionkineticsandnotadifferentpharmacodynamicactivity(e.g.,stimulationof
peripheralglucoseuptake)[75] .
Itiscriticalthatinsulinglarginenotbemixedinthesamesyringewithanyanotherinsulinorsolutionbecausethiswill
http://www.ncbi.nlm.nih.gov/books/NBK278938/?report=printable
10/24
25/06/2015
InsulinPharmacology,TypesofRegimens,andAdjustmentsEndotextNCBIBookshelf
alteritspHandthusaffectitsabsorptionprofile.Lantusmaybegivenatanytimeofday.Insulinglarginehasbeen
showntohavelessnocturnalhypoglycemiawhenusedatbedtimecomparedwithNPHinsulin[76] [77] .
InsulinDetemir(Levemir)
Insulindetemirisalongactinghumaninsulinanalogformaintainingthebasallevelofinsulinitstradenameis
Levemir.ItisaninsulinanaloginwhichtheB30aminoacidisomittedandaC14fattyacidchain(myristicacid)is
boundtotheB29lysineaminoacid.Insulindetemirisslowlyabsorbedduetoitsstrongassociationwithalbumininthe
subQtissueandwhenitreachesthebloodstreamitagainbindstoalbumindelayingitsdistributiontotheperipheral
tissues.
Storage
Allinsulinshaveanexpirationdatewhichislabeledondirectlyontheproduct(vials,cartridges,disposablepensand
otherdeliverydevices)applieswhentheyareunopenedandrefrigerated.Unopened(i.e.,insulinnotcurrentlyinuse)
insulinshouldbestoredintherefrigeratorat36F46F(2C8C).Insulinshouldneverbefrozenorstoredinan
ambienttemperaturegreaterthan86F(30C).Aninsulinvialinusemaybekeptatroomtemperature,below86
F,or30C(insulinglulisineandNovoNordiskhumaninsulins,N,Rand70/30,shouldbestoredupto77F
only),for28days,orabout1month(exceptforinsulindetemirandNovoNordiskhumaninsulins,whichcanbekept
forupto42days).Insulincartridges,disposablepensandotherdeliverydevicescanhavedifferentstorage
recommendationsforroomtemperature.Onceopened,insulincartridgesandpensshouldnotberefrigerated.
AdverseEffects
Themostsignificantadverseeffectofinsulinishypoglycemia.IntheDCCT(DiabetesControlandComplications
Trial),intensiveinsulintherapywasassociatedwitha23foldincreaseinseverehypoglycemia(i.e.,apersonrequiring
assistance)[78] .Likewise,intheUKPDS(UnitedKingdomProspectiveDiabetesStudy),insulintherapyinthe
intensivelytreatedgroupresultedin1.8%rateofmajorhypoglycemicepisodescomparedto0.7%intheconventional
group[79] .Allpatientsreceivinginsulinshouldbeawareofthesymptomsofhypoglycemiaandhowtotreatit.
Weightgainisanothersignificantsideeffectofinsulintherapy.Inpart,theweightgaincanbearesultoffrequent
hypoglycemicepisodesinwhichpatientsoftenovertreat/overeatinresponsetohunger.Insulin,beingananabolic
hormone,alsopromotestheuptakeoffattyacidsintoadiposetissue.TheamountofweightgainintheDCCTand
UKPDSassociatedwithinsulintherapywas4.6kgand4.0kgrespectively[80] [81] .However,lessweightgainis
encounteredwithlongactinginsulinanalogs[82] [83] .
Trueallergicreactionsandcutaneousreactionsarerare(seeImmunogenicity).Toavoidlipohypertrophy,patientsshould
beinstructedtorotatetheirinsulininjectionsites,preferablyrotatingwithinonearea(e.g.,abdomenavoid2inchradius
aroundnavel)andnotreusingforoneweek[84] .
InJune2009,4retrospective,epidemiologicstudiesassessingtheriskofcancerfrominsulinuse,glargineinparticular,
werepublishedonlineattheEuropeanAssociationfortheStudyofDiabetes'journalwebsite3oftheseEuropean
studiesreportedanincreasedriskofcancerwithinsulinglargine.IntheGermanystudy,acorrelationbetweeninsulin
doseandcancerriskwasfoundforallinsulintypes(humaninsulin,aspart,lisproorglargine)howeverafteradjusting
fordose,insulinglarginewasfoundtohaveadosedependentincreasedriskofcancercomparedtohumaninsulin(e.g.,
HR1.09,1.19and1.31foratotaldailydosesof10units,30unitsand50unitsrespectively).[85] Themedianfollow
uptimewasonly1.63years(1.31yearsforinsulinglargine)andbodymassindexwasnotaccountedfor.TheSwedish
studyfoundastatisticallysignificantincreasedriskofbreastcanceronlyinwomenwhousedinsulinglarginealone(RR
1.99),butnotinthoseoninsulinglargineplusotherinsulins.[86] TheScotlandstudydemonstratedaincreasedriskof
cancer(HR1.55)forpatientsoninsulinglarginealone,whilethoseoninsulinglargineplusotherinsulinshadaslightly
lowerincidenceofcancer(HR0.81)comparedtohumaninsulinonlyuserswhichwasnotstatisticallysignificant.[87]
http://www.ncbi.nlm.nih.gov/books/NBK278938/?report=printable
[88]
11/24
25/06/2015
InsulinPharmacology,TypesofRegimens,andAdjustmentsEndotextNCBIBookshelf
Finally,intheUKstudy,nolinkbetweeninsulinglargineandcancerwasfound.[88] Theseobservationalstudies
assessedlargepatientdatabasesandhavesignificant,inherentlimitationstogeneralizetheirconclusions,suchasthe
potentialfordifferentpretreatmentcharacteristicsofthegroups,selectionbias,thesmallnumbersofcancercasesfound,
andshortdurationoffollowup.Also,type2diabetesitselfisassociatedwithanincreasedriskofcolon,pancreasand
breastcancer.Furthermore,inarandomised,5year,openlabeltrialcomparingtheprogressionofretinopathyofNPH
andinsulinglargineusers,noincreasedriskofcancerwasfoundinthe1017patientsample.[89] Lastly,inananalysis
of31randomizedcontrolledtrialsfromthesanofiaventissafetydatabase(phase2,3,and4studies),insulinglargine
wasnotassociatedwithanincreasedriskofcancer,includingbreastcancer.[90] Ofnote,themainstudyaffectingthese
findingsistheRosenstocketalstudycomparingglarginetoNPHthathadanapproximate5yearduration,whereas19
ofthestudiesincludedhadveryshortdurations(approximately6months).OnJuly1,2009,theFDAissuedanearly
communicationaboutthesafetyofLantusandisworkingwiththemanufacturertoreviewthecollectivedataand
determinewhetheradditionalstudiesneedtobeperformed.Atthistime,thesedatadonotprovideconclusiveevidence
ofanincreasedriskofcancerassociatedwithinsulinglargine.
TYPESOFREGIMENS
GeneralPrinciples
Type1Diabetes
Withdecreasingbetacellfunctionresultingindecreasedinsulinproduction,peoplewithtype1diabetesmayrequire
insulinforsurvival.Ingeneral,insulinopenictype1diabeticsgenerallyrequire0.51.0unitsperkgofbodyweightper
dayofinsulin[91] .Insulintherapyisofteninitiatedat0.50.75units/kg/day[92] .Duringtheearlystagesoftype1
diabetes,patientswillrequirelessinsulinbecausethebetacellsarestillproducingsomeinsulininsulinrequirementscan
beintherangeof0.10.6unitsperkgperday[93] [94] .Intensiveinsulintherapy(definedas3insulininjections
daily)isindicatedforpeoplewithtype1diabetesasthishasbeenshowntoprovidebetterglycemiccontrolthan1or2
dailyinjectionsandreducethedevelopmentandprogressionofmicrovascularcomplications[95] .
Type2Diabetes
Manypatientswithtype2diabeteswilleventuallyrequireinsulintherapy.Sincetype2diabetesisassociatedwith
insulinresistance,insulinrequirementscanexceed1unit/kg/day.IntheUKPDS,by9yearslessthan25%ofpatients
treatedwithasulfonylureaasmonotherapywereabletomaintainA1Clevels<7.0%themajorityofpatientsrequired
insulintherapywithin9yearsofdiagnosis[96] .Wheninitiatinginsulintherapyinpatientswithtype2diabetes,insulin
isoftenusedincombinationwiththeoralmedicationsapatientistaking.Oftenanintermediatetolongactinginsulin
(e.g.,NPH,insulinglargine,orinsulindetemir)isaddedatbedtimeor70/30insulinbeforedinner[97] .Therationaleis
thatinsulin,bysuppressinghepaticglucoseoutputduringthenight,willcontrolthefastingbloodglucose(FPG),while
theoralmedication(s)continuestocontrolprandialglucoselevelsandglucosethroughouttheday[98] .Typically,a
startingdoseof10unitsisutilized,or~0.10.2units/kg[99] .Theintermediatetolongactinginsulinistitratedto
achievetheFPGtarget(seeAdjustmentsbelow).Ifthepatienthaspoorglycemiccontrolduringtheday,daytimeinsulin
caninitiatedtwicedailyregimenofinsulinormultipledailyinjectionscanbeused.Atthispoint,thepatientis
experiencingbetacellfailure.Ifthepatientistakinganinsulinsecretagogue(e.g.,glyburide,repaglinide,etc),itshould
bediscontinued,asinsulinwillnowbereplacedexogenously.However,theinsulinsensitizingoralagents(e.g.,
metforminshouldbecontinued)Anotheroptionistodiscontinuetheinsulinsecretagoguewheninsulintherapyisstarted
tosimplifythemedicationregimenandtoavoidpotentialhypoglycemia.[100] .
GoalsofTherapy
Beforestartingapatientoninsulin,oradjustingtheircurrentinsulintherapy,itisimportanttoestablishglycemicgoals
tailoredtothepatient.TheAmericanDiabetesAssociationcurrentlyrecommendsthefollowingglycemicgoals[101] :
http://www.ncbi.nlm.nih.gov/books/NBK278938/?report=printable
12/24
25/06/2015
InsulinPharmacology,TypesofRegimens,andAdjustmentsEndotextNCBIBookshelf
Preprandialplasmaglucose70130mg/dl
Postprandialplasmaglucose<180mg/dl
A1C<7%
Forexample,ifapatientspreprandialbloodglucoselevelshavebeeninthehigh200s,aninitialgoalmightbe
tolowerthemto150mg/dl.Uponachievingthis,alowergoalcanbeset(e.g.,90130mg/dl).IntheDCCT,
retinopathyinitiallyworsenedduringthefirstyearinpatients(withtype1diabetes)whoreceivedintensivetherapy[102
]
.Thisisthoughttobeduetorapidloweringofglucoselevels.Thusinpatientswithproliferativeretinopathyorthose
withhighA1C(e.g,>10%),slowerloweringofglucoseiswarranted[103] .Anotherexampleofindividualizing
glycemicgoalsisapatientwithhypoglycemicunawarenessglycemicgoalsshouldbelessaggressiveasglucoselevels
shouldnotborderaround70mg/dltooclosely.
ReplacementStrategies
PhysiologicInsulinReplacement
Afunctioningpancreasreleasesinsulincontinuously,tosupplyabasalamounttosuppresshepaticglucoseoutput
betweenmealsandovernight,andalsoreleasesabolusofinsulinprandiallytopromoteglucoseutilizationaftereating[
104]
.Replacinginsulininamannerthatattemptstomimicphysiologicinsulinreleaseisoftenreferredtoasthe
basal/bolusconcept.Thisphysiologicreplacementrequiresmultipledailyinjections(3ormore)oruseofaninsulin
pump.Basalinsulinrequirementsareapproximately50%ofthetotaldailyamount.Prandialinsulinis~1020%ofthe
totaldailyinsulinrequirementateachmeal[105] .Providingbasalbolusinsulinregimensallowpatientstohave
flexibilityintheirmealtimesandachievebetterglycemiccontrol.
NonPhysiologicInsulinReplacement
Wheninsulinisgivenonceortwicedaily,insulinlevelsdonotmimicphysiologicinsulinreleasepatterns.Forpeople
withtype2diabetes,inwhombasalinsulinreplacementisnotascritical,onceortwicedailyregimenscanstillwork
satisfactorilywithreasonableglycemiccontrolachieved.
ExamplesofRegimens
OnceDailyInsulinRegimen(forpatientswithtype2diabetesonoralagents)
NPH(Figure5a),insulinglargine(Figure5b),orinsulindetemiraremostoftengivenatbedtime(howeverinsulin
glarginecanbeadministeredanytimeoftheday)orforpatientwhoeatlargeamountsofcarbohydratesatdinner,an
insulinmixture,regularandNPHoraprexmixedinsulin,canbegivenpriortodinner(Figure5c).
http://www.ncbi.nlm.nih.gov/books/NBK278938/?report=printable
13/24
25/06/2015
InsulinPharmacology,TypesofRegimens,andAdjustmentsEndotextNCBIBookshelf
Figure5a.
Figure5b.
Figure5c.
TwicedailyInsulinRegimen(SplitMixedandPreMixedRegimens)
Twothirdsoftheinsulindoseisgiveninthemorningbeforebreakfastandonethirdisgivenbeforedinner.Premixed
insulinscanbeusedoramixtureofashortactinginsulin(e.g.,regular,insulinaspart/glulisine/lispro)andan
intermediateactinginsulin(e.g.,NPH)(Figure6a)[106] .
http://www.ncbi.nlm.nih.gov/books/NBK278938/?report=printable
14/24
25/06/2015
InsulinPharmacology,TypesofRegimens,andAdjustmentsEndotextNCBIBookshelf
Figure6a.
2/3totaldailydoseatbreakfast:givenas2/3NPHand1/3Regular(orinsulinaspart/glulisine/lispro)
1/3totaldailydoseatdinner:dividedinequalamountsofNPHandRegular(orinsulinaspart/glulisine/lispro)
ForpatientswhoexperiencenocturnalhypoglycemiawhenNPHisadministeredatdinnerwithashortactinginsulin,
movingtheNPHdosetobedtimehelpsreducetheriskfornocturnalhypoglycemia[107] .Conversely,NPHatdinner
canresultinfastinghyperglycemiaduetodissipationofinsulinactivityandthedawnphenomenon.MovingtheNPH
dosetobedtimecanhelpresolvethisproblem[108] (Figure6b).Anobviouslimitationtousingpremixedinsulinis
reducedflexibilityindosingifthedoseisadjusted,bothtypesofinsulininthemixtureareadjusted.
Figure6b.
MultipleDailyInsulinInjectionRegimen:BasalplusPrandialInsulin
Manydifferenttypesofregimensarepossiblewithmultipledailyinjections.Regular,insulinaspart,glulisineandlispro
areusedtoprovideprandialinsulin.NPH,insulinglargine,andinsulindetemirareusedtoprovidebasalinsulin.
Regular,insulinaspart/glulisine/lisprobeforemealsandNPH,insulinglargineorinsulindetemiratbedtime
(Figure7a,7b).
Insulinaspart/glulisine/lisprobeforemealsandNPHtwicedaily(breakfastandbedtime)(Figure8).
http://www.ncbi.nlm.nih.gov/books/NBK278938/?report=printable
15/24
25/06/2015
InsulinPharmacology,TypesofRegimens,andAdjustmentsEndotextNCBIBookshelf
Figure7a.
Figure7b.
Figure8.
InsulinPumps
Insulinpumporcontinuoussubcutaneousinsulininfusion(CSII)therapyisanotheroptionforintensiveinsulintherapy.
Whilepumptherapyusedtobereservedforprimarilytype1diabetes,patientswithtype2diabetesarenowusing
insulinpumps[109] .Patientsinitiatedoninsulinpumptherapyneedtobeveryknowledgeableaboutdiabetes
managementandbepracticingselfmanagement.Patientsalreadyknowhowtocountcarbohydratesandadjusttheir
http://www.ncbi.nlm.nih.gov/books/NBK278938/?report=printable
16/24
25/06/2015
InsulinPharmacology,TypesofRegimens,andAdjustmentsEndotextNCBIBookshelf
insulindoses.Potentialadvantagesofinsulinpumpsincludelessweightgain,lesshypoglycemia,andbettercontrolof
fastinghyperglycemiaduetothedawnphenomenoncomparedtomultipledailyinjections[110] [111] [112] [113] .
TimingofPrandialInsulinInjection
Thelagtimefrominjectingregularinsulinandeatingisapproximately30minuteswhileinsulinaspart/glulisine/lispro
canbeinjectedwithin15minutesofeating.Dependingonthelevelofhyperglycemiabeforemeals,thelagtimecanbe
increased.Rapidactinginsulinsallowpatientstoadjustinsulintomatchtheirlifestyleratherthanhavingtoadaptthe
timingofmealstoamorefixedinsulinregimen[114] .
Adjustments
Insulindosesshouldbeadjustedtoachieveglycemictargets.Itisalwaysbesttoerrontheconservativesidewhen
dosinginsulinatinitiationorwhenadjustingcurrentinsulintherapy.Typicallya1020%increaseordecreaseinan
insulindoseisappropriate.Ifapatientisexperiencinghypoglycemia,adjustmentoftheinsulindosecausingthe
hypoglycemiashouldbeaddressedpreferentiallyoverotherinsulindoseadjustments.Hyperglycemiaisadominoeffect:
ifapatientishyperglycemicinthemorning,chancesaretheyremainhyperglycemicthroughouttheday.Therefore,
adjusttheearliesttimeofhyperglycemiafirst[115] .
AdjustmentofIntermediatetoLongActingInsulin
Whenadoseofintermediateorlongactinginsulinisadjusted,itisrecommendedtowaitatleast25daysbeforefurther
changesinthedosetoassesstheresponse[116] .
AdjustmentofOnceDailyEveningInsulin
TheFPGisusedtoadjusttheintermediatetolongactinginsulingivenintheevening.Acommonweeklytitration
scheduleusedis[117] :
IftheFPGis>140mg/dl:Increaseby4units
IftheFPGis120140mg/dl:Increaseby2units
Forinsulinglargine,thefollowingtitrationschedulehasbeenstudiedandshowntocauselessnocturnalhypoglycemia
comparedtobedtimeNPHinsulin.Inthisstudy,insulinwastitrated,usingaforcedtitrationschedule,totargetaFPGof
100mg/dl[118] .
ForcedTitrationScheduleStartwith10unitsbedtimebasalinsulindoseadjustweekly
FPG(mg/dL)
Increaseinsulindose
100120
120140
140180
180
Decreaseinsulindose(e.g.,24units/day)ifhypoglycemiaoccurs.(modifiedrecommendationfromreference112)
SupplementalInsulinforCorrectionofHyperglycemia
Regularinsulin,insulinaspart/glulisine/lisprocanbeusedtocorrectforhyperglycemia[119] .Ingeneral,12unitsof
insulinwilllowerthebloodglucoseby3050mg/dl.Often1unitforevery50mg/dlabovetheglucosetargetisa
startingsupplementaldose,adjustingforinsulinsensitivity[120] .Anexampleofasupplementalinsulinregimenisas
follows:Forevery50mg/dlabovethepremealglucosetarget(e.g.,150mg/dl),add1unitofinsulin[121] .So,ifa
http://www.ncbi.nlm.nih.gov/books/NBK278938/?report=printable
17/24
25/06/2015
InsulinPharmacology,TypesofRegimens,andAdjustmentsEndotextNCBIBookshelf
personspremealglucosewas250mg/dl,2unitsofinsulinwouldbeaddedtotheusualdoseofpremealinsulin.
Supplementalinsulincanalsobeusedforsnacks[122] .
CarbohydrateCounting
Amoresophisticatedtypeofinsulinregimenisoneinwhichapatientdosestheirprandialinsulinbasedonthenumber
ofcarbohydrateseatenatthemeal.Bylearninghowtocounttheircarbohydrates,anddosingtheirinsulinaccordingly,
patientsareaffordedflexibilityintheirmeals.Astartinginsulintocarbohydraterationoftenusedis1unitofinsulinfor
every15gramsofcarbohydrate[123] .Thisratioisadjustedbasedoninsulinsensitivityandmaybedifferentforeach
meal.Carbohydratecountingistoodifficultforsomepatients.Inthesepatients,mealportionsizesandestimatesof
carbohydrateservings(15grams)areconceptsthatcanbelearned.Medicalnutritiontherapyisacriticalcomponentof
therapyforpatientsoninsulin.
Acomprehensivediabeteseducationclass,thatteachesselfmanagementskills,suchashowtodoseprandialinsulinby
matchingittotheamountofcarbohydrateintakeareanexcellentresourcetofacilitatepatientsinadoptinganintensive
insulintherapyregimen[124] .
AdjustmentsforExercise
Exerciseimprovesinsulinsensitivity.Thus,whenapatientexercises,itisoftennecessarytodecreasetheinsulindose
(andincreasecaloricintake).Formorningexercise,theprebreakfastinsulindoseshouldbereduced(~25%depending
onthedurationandintensityoftheexercise).Forlatemorning/earlyafternoonandeveningexercise,theprelunchand
predinnerinsulindoseshouldbereducedrespectively[125] .Theeffectofexerciseoninsulinsensitivitycanlastfor
manyhourssoseveralinsulindosesmayneedtobeadjusted.
SelfMonitoringofBloodGlucose
Patientswhowerenotselfmonitoringtheirbloodglucose(SMBG)levelspriortoinsulinneedtobeeducatedhowtodo
this,howtointerprettheirglucosereadings,andhowtotreathypoglycemiaifitoccurs.Involvementofdiabetes
educatorisextremelyusefulwheninitiatingpatientsoninsulintoprovidecomprehensiveselfmanagementtraining.The
ADAcurrentlyrecommendthatpeoplewithtype1diabetesSMBGatleast3timesdailyandthosewithtype2diabetes
atleastdaily[126] .Mostglucosemetersarenowplasmareferenced,correlatingbettertotheADAsglycemic
goals.Plasmaglucoseconcentrationsareapproximately1015%higherthanwholebloodglucoseconcentrations[127] .
SICKDAYGUIDELINES
Acommonmisconceptionamongpatientsisthatiftheyaresickenoughthattheydonteatorevenvomit,they
shouldnottaketheirdiabetesmedications,insulinincluded.Patientsshouldbeinstructedtocontinuetheirinsulin
therapy,maintainfluidintake,eatsmallermealsastolerated,andtesttheirglucoselevelsevery14hours(ketonesas
wellforpeoplewithtype1diabetes).Insulintherapyshouldbeadjustedbasedontheglucoselevels.Iftheglucoseis
>240mg/dlwithmoderatetolargeketonuria,patientsshouldcontacttheirproviderimmediately[128] .
References
1. BinderC,BrangeJ1997Insulinchemistryandpharmacokinetics.In:PorteD,Jr.,SherwinR(eds)Ellenberg'sand
Rifkin'sDiabetesMellitus,5theditioned.AppletonandLange,Stamford,CT,p689.
2. FDA/CDERresourcespage.Frequentlyaskedquestionsaboutimportingbeeforporkinsulinforpersonaluse.Food
andDrugAdministrationwebsite.Availableat:http://www.fda.gov/cder/drug/beefandporkinsulin/default.htm.
AccessedSeptember16,2006.
3. BinderC,BrangeJ1997Insulinchemistryandpharmacokinetics.In:PorteD,Jr.,SherwinR(eds)Ellenberg'sand
Rifkin'sDiabetesMellitus,5theditioned.AppletonandLange,Stamford,CT,p689.
4. May2004EliLillyandCompany.HumalogPackageInsert.
http://www.ncbi.nlm.nih.gov/books/NBK278938/?report=printable
18/24
25/06/2015
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
30.
31.
32.
33.
34.
InsulinPharmacology,TypesofRegimens,andAdjustmentsEndotextNCBIBookshelf
March2005EliLillyandCompany.HumalogMix75/25PackageInsert.
February2006SanofiAventisU.S.LantusPackageInsert.
October2005NovoNordisk,Inc.NovologPackageInsert.
November2005NovoNordiskInc.NovologMix70/30PackageInsert.
January2006EliLillyandCompany.HumalogMix50/50PackageInsert.
October2005NovoNordiskInc.LevemirPackageInsert.
November2005AventisPharmaceuticalsInc.ApidraPackageInsert.
KurtzhalsP,SchafferL,SorensenA,etal.2000Correlationsofreceptorbindingandmetabolicandmitogenic
potenciesofinsulinanalogsdesignedforclinicaluse.Diabetes49:9991005.[PubMed:10866053]
KurtzhalsP,SchafferL,SorensenA,etal.2000Correlationsofreceptorbindingandmetabolicandmitogenic
potenciesofinsulinanalogsdesignedforclinicaluse.Diabetes49:9991005.[PubMed:10866053]
HomePD,AshwellSG2002Anoverviewofinsulinglargine.DiabetesMetabResRev18Suppl3:S5763.
[PubMed:12324987]
SchernthanerG1993Immunogenicityandallergenicpotentialofanimalandhumaninsulins.DiabetesCare16
Suppl3:15565.[PubMed:8299472]
SchernthanerG1993Immunogenicityandallergenicpotentialofanimalandhumaninsulins.DiabetesCare16
Suppl3:15565.[PubMed:8299472]
BinderC,BrangeJ1997Insulinchemistryandpharmacokinetics.In:PorteD,Jr.,SherwinR(eds)Ellenberg'sand
Rifkin'sDiabetesMellitus,5theditioned.AppletonandLange,Stamford,CT,p689.
BinderC,BrangeJ1997Insulinchemistryandpharmacokinetics.In:PorteD,Jr.,SherwinR(eds)Ellenberg'sand
Rifkin'sDiabetesMellitus,5theditioned.AppletonandLange,Stamford,CT,p689.
SchernthanerG1993Immunogenicityandallergenicpotentialofanimalandhumaninsulins.DiabetesCare16
Suppl3:15565.[PubMed:8299472]
SchernthanerG1993Immunogenicityandallergenicpotentialofanimalandhumaninsulins.DiabetesCare16
Suppl3:15565.[PubMed:8299472]
SchernthanerG1993Immunogenicityandallergenicpotentialofanimalandhumaninsulins.DiabetesCare16
Suppl3:15565.[PubMed:8299472]
March2007sanofiaventisU.S.LCC.LantusPackageInsert.
BinderC,BrangeJ1997Insulinchemistryandpharmacokinetics.In:PorteD,Jr.,SherwinR(eds)Ellenberg'sand
Rifkin'sDiabetesMellitus,5theditioned.AppletonandLange,Stamford,CT,p689.
BinderC,BrangeJ1997Insulinchemistryandpharmacokinetics.In:PorteD,Jr.,SherwinR(eds)Ellenberg'sand
Rifkin'sDiabetesMellitus,5theditioned.AppletonandLange,Stamford,CT,p689.
KroonLA,AssemiM,CarlisleBA.2009DiabetesMellitus.In:AppliedTherapeutics:TheClinicalUseofDrugs,
9thedition.KodaKimbleMA,YoungLY,AlldredgeBA,CorelliRL,GuglielmoBJ,KradjanWA,WilliamsBR,
eds.Lippincott,Williams&Wilkins:Baltimore,MD.
BinderC,BrangeJ1997Insulinchemistryandpharmacokinetics.In:PorteD,Jr.,SherwinR(eds)Ellenberg'sand
Rifkin'sDiabetesMellitus,5theditioned.AppletonandLange,Stamford,CT,p689.
BinderC,BrangeJ1997Insulinchemistryandpharmacokinetics.In:PorteD,Jr.,SherwinR(eds)Ellenberg'sand
Rifkin'sDiabetesMellitus,5theditioned.AppletonandLange,Stamford,CT,p689.
March2009EliLillyandCompany.HumalogPackageInsert.
March2008NovoNordisk,Inc.NovologPackageInsert.
February2009sanofiaventisU.S.LCC.ApidraPackageInsert.
terBraakEW,WoodworthJR,BianchiR,etal.1996Injectionsiteeffectsonthepharmacokineticsand
glucodynamicsofinsulinlisproandregularinsulin.DiabetesCare19:143740.[PubMed:8941480]
March2007sanofiaventisU.S.LCC.LantusPackageInsert.
BinderC,BrangeJ1997Insulinchemistryandpharmacokinetics.In:PorteD,Jr.,SherwinR(eds)Ellenberg'sand
Rifkin'sDiabetesMellitus,5theditioned.AppletonandLange,Stamford,CT,p689.
KurtzhalsP,SchafferL,SorensenA,etal.2000Correlationsofreceptorbindingandmetabolicandmitogenic
http://www.ncbi.nlm.nih.gov/books/NBK278938/?report=printable
19/24
25/06/2015
35.
36.
37.
38.
39.
40.
41.
42.
43.
44.
45.
46.
47.
48.
49.
50.
51.
52.
53.
54.
55.
56.
57.
58.
59.
InsulinPharmacology,TypesofRegimens,andAdjustmentsEndotextNCBIBookshelf
potenciesofinsulinanalogsdesignedforclinicaluse.Diabetes49:9991005.[PubMed:10866053]
HomePD,AshwellSG2002Anoverviewofinsulinglargine.DiabetesMetabResRev18Suppl3:S5763.
[PubMed:12324987]
BinderC,BrangeJ1997Insulinchemistryandpharmacokinetics.In:PorteD,Jr.,SherwinR(eds)Ellenberg'sand
Rifkin'sDiabetesMellitus,5theditioned.AppletonandLange,Stamford,CT,p689.
FrancisAJ,HanningI,AlbertiKG1985Theinfluenceofinsulinantibodylevelsontheplasmaprofilesandaction
ofsubcutaneouslyinjectedhumanandbovineshortactinginsulins.Diabetologia28:3304.[PubMed:3899818]
terBraakEW,WoodworthJR,BianchiR,etal.1996Injectionsiteeffectsonthepharmacokineticsand
glucodynamicsofinsulinlisproandregularinsulin.DiabetesCare19:143740.[PubMed:8941480]
NolteMS,Karam,J.H.2001PancreaticHormones&AntidiabeticDrugs.In:KatzungB(ed)BasicandClinical
Pharmacology,8thed.LangeMedicalBooks/McGrawHill,NewYork,pp711734.
RabkinR,RyanMP,DuckworthWC1984Therenalmetabolismofinsulin.Diabetologia27:3517.[PubMed:
6389240]
RoachP,WoodworthJR2002Clinicalpharmacokineticsandpharmacodynamicsofinsulinlispromixtures.Clin
Pharmacokinet41:104357.[PubMed:12403642]
RaveK,etal.2005Timeactionprofileofinhaledinsulinincomparisonwithsubcutaneouslyinjectedinsulinlispro
andregularhumaninsulin.DiabetesCare2810771082.[PubMed:15855570]
PlankJ,etal.2005.Adoubleblind,randomized,doseresponsestudyinvestigatingthepharmacodynamicand
pharmacokineticpropertiesofthelongactinginsulinanalogdetemir.DiabetesCare2811071112.[PubMed:
15855574]
LeporeM,etal.2000.Pharmacokineticsandpharmacodynamicsofsubcutaneousinjectionoflongactinghuman
insulinanalogglargine,NPHinsulin,andultralentehumaninsulinandcontinuoussubcutaneousinfusionofinsulin
lispro.Diabetes4921422148.[PubMed:11118018]
March2009EliLillyandCompany.HumalogPackageInsert.
March2009EliLillyandCompany.HumalogMix75/25PackageInsert.
March2007sanofiaventisU.S.LCC.LantusPackageInsert.
March2008NovoNordisk,Inc.NovologPackageInsert.
October2007NovoNordiskInc.NovologMix70/30PackageInsert.
May2007NovoNordiskInc.LevemirPackageInsert.
KurtzhalsP,SchafferL,SorensenA,etal.2000Correlationsofreceptorbindingandmetabolicandmitogenic
potenciesofinsulinanalogsdesignedforclinicaluse.Diabetes49:9991005.[PubMed:10866053]
HomePD,AshwellSG2002Anoverviewofinsulinglargine.DiabetesMetabResRev18Suppl3:S5763.
[PubMed:12324987]
KroonLA,AssemiM,CarlisleBA.2009DiabetesMellitus.In:AppliedTherapeutics:TheClinicalUseofDrugs,
9thedition.KodaKimbleMA,YoungLY,AlldredgeBA,CorelliRL,GuglielmoBJ,KradjanWA,WilliamsBR,
eds.Lippincott,Williams&Wilkins:Baltimore,MD,pp5017.
terBraakEW,WoodworthJR,BianchiR,etal.1996Injectionsiteeffectsonthepharmacokineticsand
glucodynamicsofinsulinlisproandregularinsulin.DiabetesCare19:143740.[PubMed:8941480]
FrancisAJ,HanningI,AlbertiKG1985Theinfluenceofinsulinantibodylevelsontheplasmaprofilesandaction
ofsubcutaneouslyinjectedhumanandbovineshortactinginsulins.Diabetologia28:3304.[PubMed:3899818]
NolteMS,Karam,J.H.2001PancreaticHormones&AntidiabeticDrugs.In:KatzungB(ed)BasicandClinical
Pharmacology,8thed.LangeMedicalBooks/McGrawHill,NewYork,pp711734.
RabkinR,RyanMP,DuckworthWC1984Therenalmetabolismofinsulin.Diabetologia27:3517.[PubMed:
6389240]
BinderC,BrangeJ1997Insulinchemistryandpharmacokinetics.In:PorteD,Jr.,SherwinR(eds)Ellenberg'sand
Rifkin'sDiabetesMellitus,5theditioned.AppletonandLange,Stamford,CT,p689.
PampanelliS,TorloneE,IalliC,etal.1995Improvedpostprandialmetaboliccontrolaftersubcutaneousinjection
ofashortactinginsulinanaloginIDDMofshortdurationwithresidualpancreaticbetacellfunction.Diabetes
http://www.ncbi.nlm.nih.gov/books/NBK278938/?report=printable
20/24
25/06/2015
60.
61.
62.
63.
64.
65.
66.
67.
68.
69.
70.
71.
72.
73.
74.
75.
76.
77.
78.
79.
InsulinPharmacology,TypesofRegimens,andAdjustmentsEndotextNCBIBookshelf
Care18:14529.[PubMed:8722069]
BrunelleBL,LlewelynJ,AndersonJH,Jr.,GaleEA,KoivistoVA1998Metaanalysisoftheeffectofinsulin
lisproonseverehypoglycemiainpatientswithtype1diabetes.DiabetesCare21:172631.[PubMed:9773738]
LalliC,CiofettaM,DelSindacoP,etal.1999Longtermintensivetreatmentoftype1diabeteswiththeshort
actinginsulinanaloglisproinvariablecombinationwithNPHinsulinatmealtime.DiabetesCare22:46877.
[PubMed:10097931]
LalliC,CiofettaM,DelSindacoP,etal.1999Longtermintensivetreatmentoftype1diabeteswiththeshort
actinginsulinanaloglisproinvariablecombinationwithNPHinsulinatmealtime.DiabetesCare22:46877.
[PubMed:10097931]
ZinmanB,TildesleyH,ChiassonJL,TsuiE,StrackT1997InsulinlisproinCSII:resultsofadoubleblind
crossoverstudy.Diabetes46:4403.[PubMed:9032100]
KaufmanFR,HalvorsonM,KimC,PitukcheewanontP2000Useofinsulinpumptherapyatnighttimeonlyfor
children710yearsofagewithtype1diabetes.DiabetesCare23:57982.[PubMed:10834412]
RennerR,PfutznerA,TrautmannM,HarzerO,SauterK,LandgrafR1999Useofinsulinlisproincontinuous
subcutaneousinsulininfusiontreatment.Resultsofamulticentertrial.GermanHumalogCSIIStudyGroup.
DiabetesCare22:7848.[PubMed:10332682]
KumarD1997Lisproanalogfortreatmentofgeneralizedallergytohumaninsulin.DiabetesCare20:13579.
[PubMed:9283778]
RaskinP,GuthrieRA,LeiterL,RiisA,JovanovicL2000Useofinsulinaspart,afastactinginsulinanalog,asthe
mealtimeinsulininthemanagementofpatientswithtype1diabetes.DiabetesCare23:5838.[PubMed:
10834413]
March2008NovoNordisk,Inc.NovologPackageInsert.
BodeBW,StrangeP2001Efficacy,safety,andpumpcompatibilityofinsulinaspartusedincontinuous
subcutaneousinsulininfusiontherapyinpatientswithtype1diabetes.DiabetesCare24:6972.[PubMed:
11194244]
terBraakEW,WoodworthJR,BianchiR,etal.1996Injectionsiteeffectsonthepharmacokineticsand
glucodynamicsofinsulinlisproandregularinsulin.DiabetesCare19:143740.[PubMed:8941480]
February2009sanofiaventisU.S.LCC.ApidraPackageInsert.
BolliGB,OwensDR2000Insulinglargine.Lancet356:4435.[PubMed:10981882]
BolliGB,OwensDR2000Insulinglargine.Lancet356:4435.[PubMed:10981882]
HeinemannL,LinkeschovaR,RaveK,HompeschB,SedlakM,HeiseT2000Timeactionprofileofthelong
actinginsulinanaloginsulinglargine(HOE901)incomparisonwiththoseofNPHinsulinandplacebo.Diabetes
Care23:6449.[PubMed:10834424]
MudaliarS,MohideenP,DeutschR,etal.2002.Intravenousglargineandregularinsulinhavesimilareffectson
endogenousglucoseoutputandperipheralactivation/deactivationkineticprofiles.DiabetesCare25:1597602.
[PubMed:12196433]
YkiJarvinenH,DresslerA,ZiemenM.2000.Lessnocturnalhypoglycemiaandbetterpostdinnerglucosecontrol
withbedtimeinsulinglarginecomparedwithbedtimeNPHinsulinduringinsulincombinationtherapyintype2
diabetes.HOE901/3002StudyGroup.DiabetesCare23:11306.[PubMed:10937510]
RatnerRE,HirschIB,NeifingJL,GargSK,MeccaTE,WilsonCA2000Lesshypoglycemiawithinsulin
glargineinintensiveinsulintherapyfortype1diabetes.U.S.StudyGroupofInsulinGlargineinType1Diabetes.
DiabetesCare23:63943.[PubMed:10834423]
TheDiabetesControlandComplicationsTrialResearchGroup.1993.Theeffectofintensivetreatmentofdiabetes
onthedevelopmentandprogressionoflongtermcomplicationsininsulindependentdiabetesmellitus.NEnglJ
Med329:97786.[PubMed:8366922]
UKProspectiveDiabetesStudy(UKPDS)Group.1998.Intensivebloodglucosecontrolwithsulphonylureasor
insulincomparedwithconventionaltreatmentandriskofcomplicationsinpatientswithtype2diabetes(UKPDS
33).Lancet352:83753.[PubMed:9742976]
http://www.ncbi.nlm.nih.gov/books/NBK278938/?report=printable
21/24
25/06/2015
InsulinPharmacology,TypesofRegimens,andAdjustmentsEndotextNCBIBookshelf
80.
TheDiabetesControlandComplicationsTrialResearchGroup.1993.Theeffectofintensivetreatmentofdiabeteson
thedevelopmentandprogressionoflongtermcomplicationsininsulindependentdiabetesmellitus.NEnglJMed
329:97786.[PubMed:8366922]
81. UKProspectiveDiabetesStudy(UKPDS)Group.1998.Intensivebloodglucosecontrolwithsulphonylureasor
insulincomparedwithconventionaltreatmentandriskofcomplicationsinpatientswithtype2diabetes(UKPDS
33).Lancet352:83753.[PubMed:9742976]
82. MeneghiniLF,RosenbergKH,KoenenC,MerilainenMJ,LddekeHJ.2007.Insulindetemirimproves
glycaemiccontrolwithlesshypoglycaemiaandnoweightgaininpatientswithtype2diabeteswhowereinsulin
naiveortreatedwithNPHorinsulinglargine:clinicalpracticeexperiencefromaGermansubgroupofthe
PREDICTIVEstudy*Diabetes,ObesityandMetabolism9(3)418427.[PubMed:17391170]
83. RosenstockJ,DaviesM,HomePD,LarsenJ,KoenenC,SchernthanerG.2008.Arandomised,52week,treatto
targettrialcomparinginsulindetemirwithinsulinglarginewhenadministeredasaddontoglucoseloweringdrugs
ininsulinnaivepeoplewithtype2diabetes.Diabetologia51(3):408416.[PMCfreearticle:PMC2235909]
[PubMed:18204830]
84. ADA.2004.AmericanDiabetesAssociationPositionStatement.Insulinadministration.DiabetesCare27Suppl
1:S106109.[PubMed:14693942]
85. HemkinsLG,GrouvenU,BenderRetal.2009.Riskofmalignanciesinpatientswithdiabetestreatedwithhuman
insulinorinsulinsanalogues:acohortstudy.Diabetologia52:17321744.[PMCfreearticle:PMC2723679]
[PubMed:19565214]
86. JonassonJM,LjungR,TlbackMetal.2009.Insulinglargineuseandshorttermincidenceofmalignanciesa
populationbasedfollowupstudyinSweden.Diabetologia52:17451754.[PubMed:19588120]
87. ColhounHM,onbehalfoftheSDRNEpidemiologyGroup.2009.Useofinsulinglargineandcancerincidencein
Scotland:astudyfromtheScottishDiabetesResearchNetworkEpidemiologyGroup.Diabetologia52:17551765.
[PMCfreearticle:PMC2723678][PubMed:19603149]
88. CurrieCJ,PooleCD,2009.GaleEAMTheinfluenceofglucoseloweringtherapiesoncancerriskintype2
diabetes.Diabetologia52:17661777.[PubMed:19572116]
89. RosenstockJ,FonsecaV,McGillJBetal.2009.Similarriskofmalignancywithinsulinglargineandneutral
protamineHagedorn(NPH)insulininpatientswithtype2diabetes:findingsfroma5yearrandomized,openlabel
study.Diabetologia52:17781788.[PMCfreearticle:PMC2723677][PubMed:19609501]
90. HomePD,LagarenneP.2009.Combinedrandomisedcontrolledtiralexperienceofmalignanciesinstudiesusing
insulinglargine.Diabetologiadoi:10.1007/s0012500915305.[PMCfreearticle:PMC2776153][PubMed:
19756478]
91. HirschIB1999Type1diabetesmellitusandtheuseofflexibleinsulinregimens.AmFamPhysician60:234352,
23556.[PubMed:10593324]
92. HirschIB1999Type1diabetesmellitusandtheuseofflexibleinsulinregimens.AmFamPhysician60:234352,
23556.[PubMed:10593324]
93. ADA1998MedicalManagementofInsulinDependent(TypeI)DiabetesMellitus,3rdeditioned.American
DiabetesAssociation,Alexandria,VA.
94. 2002Practicalinsulin:Ahandbookforprescribingproviders.AmericanDiabetesAssociation,Alexandria,VA.
95. 1993TheDiabetesControlandComplicationsTrialResearchGroup.Theeffectofintensivetreatmentofdiabetes
onthedevelopmentandprogressionoflongtermcomplicationsininsulindependentdiabetesmellitus.NEnglJ
Med329:97786.[PubMed:8366922]
96. TurnerRC,CullCA,FrighiV,HolmanRR1999Glycemiccontrolwithdiet,sulfonylurea,metformin,orinsulin
inpatientswithtype2diabetesmellitus:progressiverequirementformultipletherapies(UKPDS49).UK
ProspectiveDiabetesStudy(UKPDS)Group.Jama281:200512.[PubMed:10359389]
97. HermannLS2000Optimisingtherapyforinsulintreatedtype2diabetesmellitus.DrugsAging17:28394.
[PubMed:11087006]
http://www.ncbi.nlm.nih.gov/books/NBK278938/?report=printable
22/24
25/06/2015
InsulinPharmacology,TypesofRegimens,andAdjustmentsEndotextNCBIBookshelf
98.
HermannLS2000Optimisingtherapyforinsulintreatedtype2diabetesmellitus.DrugsAging17:28394.[PubMed:
11087006]
99. DeWittDE,DugdaleDC2003Usingnewinsulinstrategiesintheoutpatienttreatmentofdiabetes:clinical
applications.Jama289:22659.[PubMed:12734138]
100. YkiJarvinenH2001Combinationtherapieswithinsulinintype2diabetes.DiabetesCare24:75867.[PubMed:
11315844]
101. ADA2009Standardsofmedicalcareindiabetes2009.DiabetesCare32Suppl1:S1361.[PMCfreearticle:
PMC2613589][PubMed:19118286]
102. 1993TheDiabetesControlandComplicationsTrialResearchGroup.Theeffectofintensivetreatmentof
diabetesonthedevelopmentandprogressionoflongtermcomplicationsininsulindependentdiabetesmellitus.N
EnglJMed329:97786.[PubMed:8366922]
103. RoachP,WoodworthJR2002Clinicalpharmacokineticsandpharmacodynamicsofinsulinlispromixtures.Clin
Pharmacokinet41:104357.[PubMed:12403642]
104. ADA1998MedicalManagementofInsulinDependent(TypeI)DiabetesMellitus,3rdeditioned.American
DiabetesAssociation,Alexandria,VA.
105. ADA1998MedicalManagementofInsulinDependent(TypeI)DiabetesMellitus,3rdeditioned.American
DiabetesAssociation,Alexandria,VA.
106. ADA1998MedicalManagementofInsulinDependent(TypeI)DiabetesMellitus,3rdeditioned.American
DiabetesAssociation,Alexandria,VA.
107. FanelliCG,PampanelliS,PorcellatiF,RossettiP,BrunettiP,BolliGB2002Administrationofneutralprotamine
Hagedorninsulinatbedtimeversuswithdinnerintype1diabetesmellitustoavoidnocturnalhypoglycemiaand
improvecontrol.Arandomized,controlledtrial.AnnInternMed136:50414.[PubMed:11926785]
108. FrancisAJ,HomePD,HanningI,AlbertiKG,TunbridgeWM1983Intermediateactinginsulingivenatbedtime:
effectonbloodglucoseconcentrationsbeforeandafterbreakfast.BrMedJ(ClinResEd)286:11736.[PMCfree
article:PMC1547399][PubMed:6404377]
109. RaskinP,BodeBW,MarksJB,etal.2003Continuoussubcutaneousinsulininfusionandmultipledailyinjection
therapyareequallyeffectiveintype2diabetes:arandomized,parallelgroup,24weekstudy.DiabetesCare
26:2598603.[PubMed:12941725]
110. MudaliarS,EdelmanSV2001Insulintherapyintype2diabetes.EndocrinolMetabClinNorthAm30:93582.
[PubMed:11727406]
111. BodeBW,SabbahHT,GrossTM,FredricksonLP,DavidsonPC2002Diabetesmanagementinthenew
millenniumusinginsulinpumptherapy.DiabetesMetabResRev18Suppl1:S1420.[PubMed:11921425]
112. BodeBW,TamborlaneWV,DavidsonPC2002Insulinpumptherapyinthe21stcentury.Strategiesfor
successfuluseinadults,adolescents,andchildrenwithdiabetes.PostgradMed111:6977quiz27.[PubMed:
12040864]
113. PickupJ,KeenH2002Continuoussubcutaneousinsulininfusionat25years:evidencebasefortheexpanding
useofinsulinpumptherapyintype1diabetes.DiabetesCare25:5938.[PubMed:11874953]
114. February2009.sanofiaventisU.S.LCC.ApidraPackageInsert.
115. ADA1998MedicalManagementofInsulinDependent(TypeI)DiabetesMellitus,3rdeditioned.American
DiabetesAssociation,Alexandria,VA.
116. ADA1998MedicalManagementofInsulinDependent(TypeI)DiabetesMellitus,3rdeditioned.American
DiabetesAssociation,Alexandria,VA.
117. MudaliarS,EdelmanSV2001Insulintherapyintype2diabetes.EndocrinolMetabClinNorthAm30:93582.
[PubMed:11727406]
118. RiddleMC,RosenstockJ,GerichJ2003Thetreattotargettrial:randomizedadditionofglargineorhumanNPH
insulintooraltherapyoftype2diabeticpatients.DiabetesCare26:30806.[PubMed:14578243]
119. HollemanF,vandenBrandJJ,HovenRA,etal.1996ComparisonofLysB28,ProB29humaninsulinanalog
http://www.ncbi.nlm.nih.gov/books/NBK278938/?report=printable
23/24
25/06/2015
120.
121.
122.
123.
124.
125.
126.
127.
128.
InsulinPharmacology,TypesofRegimens,andAdjustmentsEndotextNCBIBookshelf
andregularhumaninsulininthecorrectionofincidentalhyperglycemia.DiabetesCare19:14269.[PubMed:
8941477]
MudaliarS,EdelmanSV2001Insulintherapyintype2diabetes.EndocrinolMetabClinNorthAm30:93582.
[PubMed:11727406]
DeWittDE,HirschIB2003Outpatientinsulintherapyintype1andtype2diabetesmellitus:scientificreview.
Jama289:225464.[PubMed:12734137]
KongN,KitchenMM,RyderRE2000Theuseoflisproforhighsugarcontentsnacksbetweenmealsin
intensiveinsulinregimens.DiabetMed17:3312.[PubMed:10821304]
HirschIB1999Type1diabetesmellitusandtheuseofflexibleinsulinregimens.AmFamPhysician60:234352,
23556.[PubMed:10593324]
2002Traininginflexible,intensiveinsulinmanagementtoenabledietaryfreedominpeoplewithtype1diabetes:
doseadjustmentfornormaleating(DAFNE)randomisedcontrolledtrial.Bmj325:746.[PMCfreearticle:
PMC128375][PubMed:12364302]
ADA1998MedicalManagementofInsulinDependent(TypeI)DiabetesMellitus,3rdeditioned.American
DiabetesAssociation,Alexandria,VA.
ADA2009Standardsofmedicalcareindiabetes2009.DiabetesCare32Suppl1:S1361.[PMCfreearticle:
PMC2613589][PubMed:19118286]
StahlM,BrandslundI,JorgensenLG,HyltoftPetersenP,BorchJohnsenK,deFineOlivariusN2002Can
capillarywholebloodglucoseandvenousplasmaglucosemeasurementsbeusedinterchangeablyindiagnosisof
diabetesmellitus?ScandJClinLabInvest62:15966.[PubMed:12004932]
ADA1998MedicalManagementofInsulinDependent(TypeI)DiabetesMellitus,3rdeditioned.American
DiabetesAssociation,Alexandria,VA.
Copyright20002015,MDText.com,Inc.
ThiselectronicversionhasbeenmadefreelyavailableunderaCreativeCommons(CCBYNCND)license.Acopyofthelicensecanbeviewedat
http://creativecommons.org/licenses/byncnd/2.0/.
BookshelfID:NBK278938
PMID:25905175
http://www.ncbi.nlm.nih.gov/books/NBK278938/?report=printable
24/24